Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 708 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharyngeal Diseases Clear all
Completed Not applicable Interventional Results available

SPOTFIRE Sore Throat (ST) Study

NCT06713642
View directory record Official record
Conditions
Pharyngitis, Infective
Interventions
SPOTFIRE ST System
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Year and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 4, 2026, 5:57 PM EDT
Enrolling by invitation Not applicable Interventional

WeCareToFeedDysphagia to Reduce Care-partner Burden Full-scale RCT

NCT07250113
View directory record Official record
Conditions
Caregiver Burden, Alzheimer's Disease, Dementia, Oropharyngeal Dysphagia, Older Adults
Interventions
WeCareToFeedDysphagia web tool
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

NCT00064103
View directory record Official record
Conditions
Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer, Tongue Cancer
Interventions
Ad5CMV-p53 gene, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Early Phase 1 Interventional Results available

Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer

NCT03109873
View directory record Official record
Conditions
Larynx, Lip, Oral Cavity, Pharynx
Interventions
External Beam Radiation Therapy, Metformin Hydrochloride, Placebo
Radiation · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Results available

Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block

NCT01199237
View directory record Official record
Conditions
Airway Reflexes, Protective, Recovery After Neuromuscular Block, Anesthetic Recovery
Interventions
Sevoflurane, Desflurane, Rocuronium, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 4, 2026, 5:57 PM EDT
Not yet recruiting Not applicable Interventional

Deep Brain Stimulation + Therapy for Stroke

NCT07849114
View directory record Official record
Conditions
Stroke, Dysarthria, Apraxia, Dysphagia, Hemiparesis After Stroke
Interventions
Boston Scientific Vercise Deep Brain Stimulation (DBS) System, Rehabilitation Training Protocol
Device · Other
Lead sponsor
Pirondini, Elvira, PhD
Other
Eligibility
22 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis

NCT01049334
View directory record Official record
Conditions
Pharyngitis
Interventions
Placebo, Flurbiprofen
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

NCT04242199
View directory record Official record
Conditions
Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma
Interventions
INCB099280
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Not applicable Interventional

TEE and Dysphagia in Lung Transplantation

NCT06089434
View directory record Official record
Conditions
Lung Transplant, Dysphagia
Interventions
Transesophageal Echocardiography (TEE) with limited number of TEE clips, Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 4, 2026, 5:57 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Swallowing Impairments in ICU Survivors and Community-Dwelling Adults

NCT07005037
View directory record Official record
Conditions
Dysphagia, Healthy Aging, Post Intensive Care Syndrome, Caregiver Burden
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT

NCT02870101
View directory record Official record
Conditions
Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection, Sexually Transmitted Infections
Interventions
Nucleic acid amplification test 1 for NG and CT, Nucleic acid amplification test 2 for NG and CT, Nucleic acid amplification test 3 for NG and CT
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,767 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Hollywood, California • Los Angeles, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 4, 2026, 5:57 PM EDT
Not yet recruiting Phase 1 Interventional

A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma

NCT07650266
View directory record Official record
Conditions
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
Interventions
Cemiplimab, Fianlimab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function

NCT00002901
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fostering Eating After Stroke With Transcranial Direct Current Stimulation

NCT01919112
View directory record Official record
Conditions
Dysphagia, Stroke
Interventions
tDCS
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Phase 3 Interventional

APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat

NCT00242281
View directory record Official record
Conditions
Sore Throat, Pharyngitis, Tonsillitis
Interventions
APC-111 MP Tablet, 775 mg
Drug
Lead sponsor
Advancis Pharmaceutical Corporation
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
35
States / cities
Birmingham, Alabama • Tallassee, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2006 · Synced Oct 4, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

NCT07063212
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Sacituzumab Govitecan, Cetuximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 4, 2026, 5:57 PM EDT
Recruiting No phase listed Observational

DESTINY-PANTUMOUR04

NCT07124000
View directory record Official record
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 4, 2026, 5:57 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Throat Spray on the Incidence and Duration of Sickness

NCT07246850
View directory record Official record
Conditions
Sore-throat, Common Cold
Interventions
Beekeeper's Propolis Throat Spray, Placebo Throat Spray
Dietary Supplement
Lead sponsor
Beekeeper's Naturals Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00656513
View directory record Official record
Conditions
Head and Neck Cancer, Xerostomia
Interventions
Pilocarpine, ALTENS
Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
16
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 4, 2026, 5:57 PM EDT
Withdrawn Phase 2 Interventional

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

NCT04001413
View directory record Official record
Conditions
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
Interventions
MEDI0457, Durvalumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 4, 2026, 5:57 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Standardizing Swallow Pressure Measurements

NCT07475091
View directory record Official record
Conditions
Dysphagia
Interventions
Laborie LMT Pharyngeal System (3.7 mm catheter), Medtronic ManoScan ESO HRM System (4.2 mm catheter)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer

NCT04870840
View directory record Official record
Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Malignant Posterior Tongue Neoplasm, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma
Interventions
Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 4, 2026, 5:57 PM EDT
Completed No phase listed Observational Results available

Predictors of the Ability to Protect the Airway in Long-term Ventilated Patients

NCT01618240
View directory record Official record
Conditions
Swallowing Disorder, Aspiration, Long Term Ventilation
Interventions
Muscle Strength Measurement, Ventilator
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 4, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

NCT00431210
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Epstein-Barr virus-specific adoptive T-cells immunotherapy
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 4, 2026, 5:57 PM EDT